Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension
Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension On a Controlled Sodium Diet (100 mmol/Day)
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Mild-to-moderate hypertension as defined by a morning mean diastolic blood pressure from ≥ 90 and ≤ 115 mmHg and a mean systolic blood pressure ≤ 200 mmHg after five minutes in the seated position at the end of three weeks of placebo run-in treatment
- Male or female patients between 18 and 65 years of age, inclusive. Patients 60 to 65 years of age must have a screening 24-hour urine creatinine clearance rate of ≥ 1 mL/sec
- Ability to provide written informed consent
Exclusion Criteria:
- Pre-menopausal women (last menstruation ≤ one year to start of screening)
Post-menopausal women (last menstruation > one year from start of screening or have had a hysterectomy and oophorectomy)
- Who have < three months of stable estrogen replacement therapy at screening
- Who will be on progesterone therapy at any time during the trial
- Known or suspected secondary hypertension
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than two times the upper limit of reference range
- Serum creatinine greater than 2.3 mg/dL
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant
- NYHA (New York Heart Association) functional class CHF (chronic heart failure) III-IV
- Unstable angina, myocardial infarction or cardiac surgery within the preceding three months
- Stroke within the preceding six months
- PTCA (percutaneous transluminal coronary angioplasty) within the preceding three months
- History of angioedema
- Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical Investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
- Administration of digoxin or other digitalis-type drugs
- Patients with insulin-dependent and non-insulin-dependent diabetes mellitus
- History of drug or alcohol dependency
- Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, α-blockers, β-blockers, calcium channel antagonists, direct vasodilators at any time during the trial
- Administration of other non-antihypertensive medications known to affect blood pressure (e.g., oral corticosteroids, MAO (monoamine oxidase) inhibitors, nitrates) at any time during the trial
- Chronic administration of high doses of NSAIDS and aspirin (e.g., ibuprofen for rheumatoid arthritis and osteoarthritis in total daily dose in excess of 1600 mg, aspirin in excess of 2 Gm per day)
- Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions
- Clinically significant sodium depletion as defined by a serum sodium level less than 130 mEq/L
- Clinically significant hyperkalemia as defined by a serum potassium level greater than 6.0 mEq/L. Clinically significant hypokalemia as defined by a serum potassium level less than 3.0 mEq/L
- Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
- Known hypersensitivity to any component of telmisartan
- Any other clinical condition which, in the opinion of the principal Investigator, would not allow safe completion of the protocol and safe administration of trial medication
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Telmisartan, low dose
3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
|
|
|
Eksperimentell: Telmisartan, high dose
3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
|
|
|
Placebo komparator: Placebo
3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Cumulative urinary sodium loss
Tidsramme: 0-4, 4-8, 8-24 hours post-dose at baseline, day 0, day 7 and 0-24 hours post-dose on days 1-6
|
0-4, 4-8, 8-24 hours post-dose at baseline, day 0, day 7 and 0-24 hours post-dose on days 1-6
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Cumulative urine sodium loss
Tidsramme: 0-24 hours post-dose on days 8-13 and 0-4, 4-8, 8-24 hours post-dose on day 14
|
0-24 hours post-dose on days 8-13 and 0-4, 4-8, 8-24 hours post-dose on day 14
|
|
Changes in body weight
Tidsramme: 24 hours post-dose on days -28, -21 to -14, -7, -1, 0, 7, 14 and 22
|
24 hours post-dose on days -28, -21 to -14, -7, -1, 0, 7, 14 and 22
|
|
Changes in plasma norepinephrine
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in renin activity
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in aldosterone
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in urine potassium
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in creatinine chloride
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in bicarbonate
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Changes in uric acid
Tidsramme: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
|
|
Cumulative urinary sodium gain during wash-out period
Tidsramme: 0-24 hours post-dose on days from day 15 to 22
|
0-24 hours post-dose on days from day 15 to 22
|
|
Changes in seated clinic blood pressure
Tidsramme: Baseline and day 14
|
Baseline and day 14
|
|
Changes in 24 hour ambulatory Blood Pressure (ABPM) after the first dose of telmisartan
Tidsramme: Day 0
|
Day 0
|
|
Number of patients with adverse events
Tidsramme: up to 50 days
|
up to 50 days
|
|
Number of patients with abnormal findings in physical examination
Tidsramme: Baseline and day 22
|
Baseline and day 22
|
|
Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)
Tidsramme: Baseline and day 22
|
Baseline and day 22
|
|
Number of patients with abnormal changes in laboratory parameters
Tidsramme: Baseline and day 22
|
Baseline and day 22
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 502.255
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .